In : InMed Pharmaceuticals Inc Stock Profile

Last Updated: 3/12/2024 0:47:16

InMed Pharmaceuticals Inc trades with the ticker In on the TSX and is in the industry.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company’s lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Looking to invest in InMed Pharmaceuticals Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.

In.TO Stock Price and Key Stats

ETF Key Stats

Exchange: TSX

Market Cap : $33.732MM

PE Ratio:

Price: #N/A (Updated: 3/12/2024 0:47:16)

InMed Pharmaceuticals Inc (In) vs Competitors in

Lets see how In.TO stacks up against others in the asset management industry. We have identified its main peers as:

Kinder Morgan Canada Limited, Storm Resources Ltd, UrtheCast Corp, World Financial Split Corp

Industry information unavailable.
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield  

Comparisons within

  • InMed Pharmaceuticals Inc (In) vs Kinder Morgan Canada Limited (KML)
    • KML has higher EPS (0.392 vs -0.077). KML has higher dividend yield (4.4% vs 0.0%). In has a P/E under 0, indicating KML (P/E 24.048) is in a better position.
  • InMed Pharmaceuticals Inc (In) vs Storm Resources Ltd (SRX)
    • SRX has higher EPS (0.068 vs -0.077). SRX has higher dividend yield (0.0% vs 0.0%). In has a P/E under 0, indicating SRX (P/E 92.206) is in a better position.
  • InMed Pharmaceuticals Inc (In) vs UrtheCast Corp (UR)
    • In has higher EPS (-0.077 vs -0.546). UR has higher dividend yield (0.0% vs 0.0%). UR and In both have P/E’s under 0.
  • InMed Pharmaceuticals Inc (In) vs World Financial Split Corp (WFS)
    • In has higher EPS (-0.077 vs -2.142). In provides dividends, while WFS does not. WFS and In both have P/E’s under 0.

Our Recommendation: Hold
Shows positive EPS growth from this year to next, suggesting improving profitability. Features a lower EV/EBITDA ratio (0.00) than the industry average (4.80), indicating attractive valuation.

How to Buy In stock on the TSX

You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:

ImageProduct TitleFeaturesPrice
Editor's Choice
Wealthsimple Trade

Wealthsimple Trade

  • ETF buys and sells have $0 trading fees
  • Desktop and mobile trading
  • Reputable Brand
  • Beautiful Design
Get $25 Signup Bonus
Reliable Pick


  • ETF buys have $0 trading fees
  • Desktop and mobile trading
  • Most types of accounts available
Get $50 Free Stock Trades
Photo of author
Author Bio - Qayyum Rajan is a CFA Charterholder with 10+ years of finance experience and the co-creator of He has previously worked as a portfolio manager at RBC Dominion Securities and other roles at asset managers like Sentry Investments. He then started building websites and fintech apps to bring finance to everyone.

Check Out These Posts:

Leave a Comment